5 Feb 2024 , 02:21 PM
Mankind Pharma (Mankind)’s India business growth of 20/13% on a year-on-year basis in Q3/9MFY24, versus IPM growth of 8-8.5%, has been driven by its sustained outperformance in the Chronic segment, sequential recovery in acute sales during Q3, and Modern Trade (MT) & Hospital channel emerging as a new distribution channel for the company over the past few quarters. EBITDA beat of 6% in Q3 versus IIFL estimates would have been even higher, save for GM decline of ~130 basis points sequentially owing to inventory provisions and 10% under-utilization at the Sikkim plant.
On the back of consistent volume-led outperformance in the domestic market, further increase in Chronic revenue share in metros (55% for Mankind versus 70% for IPM) and strong brand building capabilities, analysts at IIFL Capital Services expect Mankind to deliver 13%/18%/19% Revenue/EBITDA/EPS CAGR over FY24-27.
Assuming a 15% growth in the base Exports business and a 50% decline in the one-off product in FY25, analysts at IIFL Capital Services expect Mankind’s overall exports business to decline 2% in FY25 over FY24. Post that, they have factored 15% CAGR in export sales.
They have upgraded their EPS estimates by 2-3% and value the stock at ~35x FY26 estimated EPS to arrive at their Target Price of ₹2,460 (21% upside). Mankind, JB Pharma and Torrent are their preferred picks among the India-focused players.
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.